title: [Prevention of congenital toxoplasmosis with spiramycin; value and limits of levels in amniotic fluid].
authors.forename: P
authors.initials: P
authors.lastname: Bourget
authors.forename: A
authors.initials: A
authors.lastname: Lesne-Hulin
authors.forename: F
authors.initials: F
authors.lastname: Forestier
authors.forename: V
authors.initials: V
authors.lastname: Desmaris
authors.forename: E
authors.initials: E
authors.lastname: Dulac
mesh_terms: D000293:Adolescent; D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies; D015572:Spiramycin / Q000032:analysis / Q000627:therapeutic use*; D014125:Toxoplasmosis, Congenital / Q000517:prevention & control*
chemical_list: D000900:Anti-Bacterial Agents; D015572:Spiramycin
vernacular_title: Prévention de la toxoplasmose congénitale par la spiramycine; intérêt et limites du dosage dans le liquide amniotique.